High Court Finds Antitrust Scrutiny Applies to Pay-for-Delay Settlements

by Bracewell LLP
Contact

On June 17, 2013, the U.S. Supreme Court determined that the Federal Trade Commission’s (FTC) antitrust challenge to a reverse payment settlement agreement between drug manufacturers, otherwise known as a “pay-for-delay” deal, may go forward, reversing the Eleventh Circuit’s dismissal of the FTC’s complaint.1 In a 5-3 decision, the majority of the Court found that these forms of settlement, whereby a branded pharmaceutical manufacturer that owns a drug patent pays a generic manufacturer some amount of money (often a large sum) to delay market entry, are “unusual,” and could have a significant adverse effect on competition.  Thus, the Court held that pay-for-delay agreements should be reviewed using a “rule of reason” analysis that weighs the pro-competitive benefits of the settlement against its potential anticompetitive effects.2 The Eleventh Circuit previously had found that the pay-for-delay agreement at issue between Solvay Pharmaceuticals, Actavis, and others was immune from antitrust scrutiny because its anticompetitive effects fell within the scope of the patent’s exclusionary potential, as it did not extend the subject matter or term of the patent.3 The Circuit Court noted in its decision the general legal policy favoring the settlement of disputes and that courts could not require parties to continue to litigate in order to escape antitrust liability.

In reversing the Eleventh Circuit, the Supreme Court stated that patent law does not immunize reverse settlement agreements from antitrust attack.  Justice Breyer, writing for the majority, explained that in pay-for-delay cases, because it is not known whether a patent is valid or whether it has been infringed, it therefore “would be incongruous to determine antitrust legality by measuring the settlement’s anticompetitive effects solely against patent law policy[...]”4  Instead, the majority concluded, both patent law policy and antitrust law policy are relevant in determining the scope of monopoly power and antitrust immunity conferred by a patent, and the antitrust question should be answered by examining traditional antitrust factors. 

Although the Court acknowledged the general legal policy of favoring the settlement of disputes, particularly in complex cases, it was not persuaded that this should prohibit antitrust scrutiny in pay-for-delay cases, for several reasons.  Delayed market entry by a cheaper generic version of a drug has the potential for “genuine adverse effects on competition,” and, at least in some cases, the anticompetitive effects cannot be justified.  Additionally, it normally should not be necessary to litigate patent validity to answer the antitrust question, and in particular, a large unexplained reverse payment can provide a proxy for a patent’s weakness.  Parties also would not be prevented from settling patent disputes in other ways. 

The FTC did not win the pay-for-delay battle on all fronts, as the Court declined to hold that reverse settlement payments are presumptively unlawful, despite the FTC urging it to do so.  Rather, the Court found the “rule of reason” approach to be more appropriate, because the likelihood of a reverse payment having an anticompetitive effect is not clear-cut and depends on several factors, such as “its size, its scale in relation to the payor’s anticipated future litigation costs, its independence from other services for which it might represent payment, and the lack of any other convincing justification.”5 The Court, therefore, acknowledged that legitimate justifications may exist for reverse payments.

In his dissent, Chief Justice Roberts noted the purpose of patent law is to grant limited monopolies in order to promote innovation and explained that the correct question to ask is whether the settlement gives the patentee monopoly power beyond what the patent already conferred on it.  The Chief Justice warned that the majority’s decision will discourage settlements of patent litigation and may also discourage generic manufacturers from challenging a branded company’s patent in the first place, due to the uncertainty regarding available settlement options.

The Supreme Court’s decision likely will make it harder for drug companies to get pay-for-delay lawsuits dismissed at the early stages of litigation and may open the floodgates to more challenges of such patent settlements.  The Supreme Court’s opinion does provide some guidance regarding the factors to be considered in determining a reverse payment’s validity, but the lower courts will need to sort out the details with respect to specific settlements, setting the stage for varied and potentially conflicting decisions by different courts.  Additionally, the decision likely will cause drug companies to structure patent settlements differently and focus more heavily on the size of reverse payments and their justifications, although it remains to be seen whether the Court’s ruling will result in fewer settlements in drug patent cases, as the dissent predicts.

____________________________________

1 Federal Trade Comm’n v. Actavis Inc., No. 12-416, 570 U.S. ___ , (2013) WL 2922122 (June 17, 2013).

2 Federal Trade Comm’n v. Actavis Inc., No. 12-416, 570 U.S. ___ , (2013) WL 2922122, at *2, 13-14 (June 17, 2013).

3 Federal Trade Comm’n v. Watson Pharm., Inc., 677 F.3d 1298, 1312 (11th Cir. 2012), rev’d sub nom. Federal Trade Comm’n v. Actavis, Inc., No. 12-416, 570 U.S. ___ , (2013) WL 2922122 (June 17, 2013).

4 Actavis, 2013 WL 2922122, at *1.

5 Id. at *13.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bracewell LLP | Attorney Advertising

Written by:

Bracewell LLP
Contact
more
less

Bracewell LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.